Short answer
Penumbra Inc (PEN) filed its Q3 2018 10-Q quarterly report on Nov 5, 2018 for the quarter ended Sep 30, 2018.
Penumbra Inc Q3 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $111.8M, up 33.2% YoY from $83.9M
- Gross margin 67.1% vs 65.3% YoY, operating margin (18.6%) vs 0.8%
- Best segment Peripheral Vascular: $37.1M, up 47.1%; Neuro $74.7M, up 27.3%
- Cash $47.7M vs $50.6M; operating cash flow $21.3M, MVI acquisition payments $19.9M
- Near-term headwinds: rising R&D and SG&A, additional product development investments, quarterly expense variability
Risk Factors
- No material changes or newly identified risk factors since the December 31, 2017 Form 10-K
- Carried-forward risks remain unchanged from the February 27, 2018 annual filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.